Reduced Final Height Outcome in Congenital Adrenal Hyperplasia under Prednisone Treatment: Deceleration of Growth Velocity during Puberty
The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
CONTEXT: Normal to decreased final height (FH) has been reported in patients with congenital adrenal hyperplasia (CAH). OBJECTIVE: The objective was to determine FH outcome and influences of steroid treatment. METHODS: The effects of glucocorticoid treatment for classical CAH were retrospectively studied in 125 patients (77 females). Growth pattern, FH, and pubertal development were recorded. RESULTS: Corrected FH was in the lower range of genetic potential [females with simple virilizing (SV)-CAH, -0.6 +/- 1.0 sd score (SDS) vs. females with salt-wasting (SW)-CAH, -0.6 +/- 0.9 SDS; males with SV-CAH, -1.1 +/- 0.9 SDS vs. males with SW-CAH, -0.9 +/- 0.9 SDS]. Total pubertal growth was significantly reduced in comparison with a reference population (females with SV-CAH, 11.9 +/- 6.5 cm, and females with SW-CAH, 13.8 +/- 7.6 cm vs. reference 20.3 +/- 6.8 cm, P < 0.01; and males with SV-CAH, 15.4 +/- 6.6 cm, and males with SW-CAH, 18.5 +/- 6.9 cm vs. reference 28.2 +/- 8.2 cm, P < 0.01). Thirty-three patients had been treated with prednisone, which resulted in reduced FH compared with patients (n = 92) treated with hydrocortisone (-1.0 +/- 0.9 SDS vs.-0.6 +/- 0.9 SDS; P < 0.05). FH correlated negatively with hydrocortisone dose given at the start of puberty (r = -0.3; P < 0.05). Pubertal development started early in boys [9.8 +/- 2.3 yr (SV) and 10.6 +/- 1.9 yr (SW)] and was timely in girls [9.8 +/- 1.9 yr (SV) and 10.3 +/- 1.5 yr (SW), menarche at 13.3 +/- 1.7 yr (SV) and 13.7 +/- 1.5 yr (SV)]. CONCLUSION: Patients with CAH are able to achieve adequate FH with conventional therapy. Total pubertal growth is significantly decreased, and treatment with prednisone results in decreased FH. In addition to biochemical analysis, treatment should be adjusted to normal growth velocity, especially during puberty.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hydrocortisone is the preferred glucocorticoid in children with CAH owing to its short half-life and the fact that it has the lowest growth suppressing effect of available glucocorticoids24,28.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [28]
In the citing paper
“However, adult height correlates negatively with glucocorticoid dose during puberty, especially doses of hydrocortisone exceeding 17 mg/m2 per day28.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [28]
In the citing paper
“The adult height of patients with CAH correlates negatively with the dose of GC administered in early puberty; patients treated with ,20 mg of HC/m 2 per day at the start of puberty are significantly taller than those given higher HC doses (187).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [187]
In the citing paper
“During childhood, the preferred GC is HC because its short half-life minimizes the adverse side effects typical of longer-acting, more potent GCs, especially growth suppression (Table 2) (187).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [187]
Citations
Cites
RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRIST
GREULICH, W. W., & PYLE, S. I. (1959) · The American Journal Of The Medical Sciences · doi:10.1097/00000441-195909000-00030 · Cited by 5,585
Body mass index reference curves for the UK, 1990.
Cole, T. J., Freeman, J. V., & Preece, M. A. (1995) · Archives of Disease in Childhood · doi:10.1136/adc.73.1.25 · Cited by 2,047
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Prader, A., Largo, R. H., Molinari, L., & Issler, C. (1989) · PubMed · Cited by 814
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Self-citationMulaikal, R. M., Migeon, C. J., & Rock, J. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701223160402 · Cited by 361
Pubertal development in Swiss boys.
Rh, L., & Prader, A. (1983) · PubMed · Cited by 234
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Pubertal development in Swiss girls.
Largo, R. H., & Prader, A. (1983) · PubMed · Cited by 200
Cited by
Items 101–161 of 161
Bonfig, W., Kapelari, K., & Riedl, S. (2019) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-019-00083-8 · Cited by 3
Self-citationLang‐Muritano, M., Gerster, K., Sluka, S. H. M., & Konrad, D. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00035 · Cited by 3
“Recent data support the recommendation that the daily HC dose should not exceed 17 mg/m2 to optimize pubertal growth (2).”
BackgroundResultInfluentialSurgical Reconstruction of the Genitalia in a 3-Year-Old Infant with a 46XX Karyotype: Case Report
Gozar, H., Pascanu, I. M., Ardelean, M., Gurzu, S., & Derzsi, Z. (2014) · Aesthetic Plastic Surgery · doi:10.1007/s00266-014-0321-7 · Cited by 2
“decrease the level of adrenal hormones and to replace the deficient hormone production, respectively [3].”
BackgroundGrowth pattern and pubertal development in patients with classic 21-hydroxylase deficiency
Bunraungsak, S., Klomchan, T., & Sahakitrungruang, T. (2013) · Asian Biomedicine · doi:10.5372/1905-7415.0706.241 · Cited by 3
“In our case series, the pubertal onset was significantly earlier in patients in both forms of CAH compared with the Thai normal reference, as previously observed in other studies [6, 7].”
BackgroundResultInfluentialShifman, B. M., Dzeranova, L. K., Pigarova, E. A., Tiulpakov, A. N., & Fedorova, N. S. (2019) · Obesity and metabolism · doi:10.14341/omet10032 · Cited by 3
Hassan, M. M., Ibrahim, A., Abdel-Salam, A., & Huthail, H. (2013) · Egyptian Pediatric Association Gazette · doi:10.1016/j.epag.2013.10.001 · Cited by 3
Saito, Y., Takasawa, K., Gau, M., Yamauchi, T., Nakagawa, R., Miyakawa, Y., Sutani, A., Tsuji‐Hosokawa, A., Takishima, S., Matsubara, Y., et al. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.155 · Cited by 2
“Although early initiation of glucocorticoid therapy from the neonatal period remarkably improved the outcomes of final height, the average final height in 21OHD patients is below the standard height observed in normal healthy adults by approximately –1 standard deviation (SD) (3, 4), and optimization of glucocorticoid…”
BackgroundPrenatal Diagnosis and Treatment of Congenital Adrenal Hyperplasia
Speiser, P. (2009) · Wiley eBooks · doi:10.1002/9781444314342.ch18 · Cited by 2
Clinical practice guidelines "Congenital adrenal hyperplasia in children" with comments
Чугунов, І., Kopylova, I., Kolodkina, A. A., Kalinchenko, N. Y., Vorontsova, M. V., Bezlepkina, O. B., Peterkova, V. A., & Mokrysheva, N. G. (2026) · Problems of Endocrinology · doi:10.14341/probl13767 · Cited by 1
Ekbom, K. (2017) · Pain Research and Treatment · doi:10.1155/2017/1793241 · Cited by 1
“Excess glucocorticoids suppress growth [7, 10], and the use of hydrocortisone has also been shown to have a positive correlation with BMI SDS.”
BackgroundDubinski, I., Marzi, C., Nennstiel, U., Schiergens, K. A., Schmidt, H., & Odenwald, B. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0389 · Cited by 2
Self-citationDiagnosis and Management of Congenital Adrenal Hyperplasia
Dhesi, A. S., & McGovern, P. G. (2014) · Postgraduate Obstetrics & Gynecology · doi:10.1097/01.pgo.0000450250.49010.9e · Cited by 1
Aspectos relevantes del tamiz neonatal para hiperplasia suprarrenal congénita
Trejo, M. A. H., Arguinzoniz-Valenzuela, S. L., Pérez, L. D. A. H., Parra, G. C., Ibarra‐González, I., Amieva, M. V., Córdova, L. E. B., Baqué, I. G., & Flores, E. P. G. (2018) · Acta Pediátrica de México · doi:10.18233/apm39no6pp14s-24-s1718 · Cited by 5
Case 2: A 4-year-old Boy with Recurrent Vomiting
Jain, S., & Karaviti, L. P. (2019) · Pediatrics in Review · doi:10.1542/pir.2017-0280 · Cited by 1
“(1)(5)(7) Adherence and disease activity are monitored by growth velocity, skin hyperpigmentation, and electrolyte, corticotropin, and renin levels.”
BackgroundTroger, T., Sommer, G., Lang‐Muritano, M., Konrad, D., Kuhlmann, B. V., Zumsteg, U., & Fluck, C. E. (2022) · Yearbook of pediatric endocrinology · doi:10.1530/ey.19.8.6 · Cited by 1
Treatment and Outcome of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency
Lee, P. A., Fuqua, J. S., & Nebesio, T. D. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/276843 · Cited by 1
Bohlmann, M. K., Hornemann, A., Weichert, J., Stichtenoth, G., Ortmann, J., Diedrich, K., & Lüdders, D. (2008) · Gynäkologische Endokrinologie · doi:10.1007/s10304-008-0265-6 · Cited by 1
Steroid Replacement in Adrenal Insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64307-6 · Cited by 1
Het fysiek, sociaal en maatschappelijk functioneren van kinderen met AGS en hun ouders.
Sanches, S. A., & Wiegers, T. A. (2010) · Data Archiving and Networked Services (DANS) · Cited by 1
Das adrenogenitale Syndrom aufgrund eines 21-Hydroxylasemangels bei Männern
Weniger, M., Reisch, N., & Kuhnle-Krahl, U. (2012) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 1
Anthropometry in Congenital Adrenal Hyperplasia
Falhammar, H., Nordenström, A., & Thorén, M. C. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1788-1_146 · Cited by 1
Kamoun, M., Feki, M. M., & Abid, M. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113718
“[1] However, alternative protocols should be considered in a subset of CAH patients with poor height prognosis due to poor hormonal control, advanced skeletal maturation, and central precocious puberty onset.[2,6,14] Further prospective, randomized, and carefully controlled studies would be helpful in determining whet…”
InfluentialMiller, R., & Radovick, S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0583
Novel Therapies for Treating Short Stature with Congenital Adrenal Hyperplasia
Simpson, J. L., Hann, M., Kshetrapal, A., & New, M. I. (2011) · International Journal of Infertility & Fetal Medicine · doi:10.5005/jp-journals-10016-1017
Avaliação do crescimento e estatura final de pacientes com hiperplasia congenita de supra-renal
Kohara, S. K. (2007) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Congenital Adrenal Hyperplasia: Diagnosis, Management, and Long Term Outcomes
Ammini, A. C. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch6
Nermoen, I. (2013) · NVA (Nasjonalt vitenarkiv)
Debates and Controversies in Genetic Steroid Disorders
Speiser, P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00030-2
Long-term steroid hormone concentrations in healthy children, in obesity, and in disease
Noppe, G. (2016) · EUR Research Repository (Erasmus University Rotterdam)
Sari, N. I. N., Tridjadja, B., Kaswandani, N., Sjarif, D. R., Putra, S. T., & Gunardi, H. (2016) · Sari Pediatri · doi:10.14238/sp16.5.2015.356-64
Application of Pharmacometrics to Rare Diseases
AHMED, M. A. (2016) · University of Minnesota Digital Conservancy (University of Minnesota)
Hauffa, B. P., Binder, G., Bonfig, W., Bettendorf, M., & Dörr, H. G. (2019) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-019-0697-1
Self-citationBhatnagar, R., Siddiqui, S. A., Rai, P. L., Tomar, V., Verma, M. K., & Sharma, P. (2019) · Tropical Doctor · doi:10.1177/0049475519879592
“The guidelines for glucocorticoid replacement in CAH suggest the use of short half-life glucocorticoids to prevent adrenal crises and virilisation and longer-acting glucocorticoids to minimise growth suppression.(7,8) During treatment, care should be taken to avoid cortisol excess because this may lead to a Cushingoid…”
Congenital Adrenal Hyperplasia in Patients with Disorders of Sexual Differentiation
Fatima, W., Rafiq, T., & Mahmood, S. (2020) · THE JOURNAL OF MICROBIOLOGY AND MOLECULAR GENETICS · doi:10.52700/jmmg.v1i3.10 · Cited by 1
“manner and consanguinity increases the chances of having a child with this defect (Bonfig et al., 2007; Hedi et al., 2005).”
An interesting case of masculine voice in a girl: A case report of 11 beta hydroxylase deficiency
Galla, H., & Vani, M. N. S. (2021) · Indian Journal of Child Health · doi:10.32677/ijch.2021.v08.i07.003
Hiperplasia congenita das supra-renais por deficiencia da 21-hidroxilase
dos Santos, C. T. M. (2007) · doi:10.47749/t/unicamp.2007.412236
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283040e80
Gleeson, H. K. (2011) · doi:10.1093/med/9780199235292.003.7145
Congenital adrenal hyperplasia in children
Riepe, F. G. (2011) · doi:10.1093/med/9780199235292.003.7122
Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
Lawrence, N., Bacila, I. A., Dawson, J., Bryce, J., van, D. A. E., Sartori, S. B. T. A., Baronio, F., Birkebæk, N., Bonfig, W., Claahsen, H., et al. (2021) · Endocrine Abstracts · doi:10.1530/endoabs.78.p1
Self-citationDebates and controversies in genetic steroid disorders
Speiser, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00014-9
Bone mineral density and skeletal outcomes in congenital adrenal hyperplasia
Robinson, C., Yuen, T., & Zaidi, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00006-x
McCracken, C., Kaabi, O., Crawford, M., Gardner, M. D., Getahun, D., Goodman, M. G., Khorashad, B. S., Lash, T. L., Roblin, D. W., Vupputuri, S. X., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.005
Steroid replacement in adrenal insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00147-3
Chong, H., Pi, Y., Zhang, Y., Li, Y., Xing, Y., & Zhang, H. (2025) · BMC Pediatrics · doi:10.1186/s12887-025-05643-3
“After puberty initiation, BA – CA in SW-phenotype patients worsened, and the H BA SDS – THSDS significantly decreased in SW-males, indicating further reduction in growth potential and diminished pubertal growth, consistent with prior findings [14].”
Hyperplasie congénitale des surrénales : formes précoces
Levaillant, L., Bouhours‐Nouet, N., Rouleau, S., Amsellem‐Jager, J., Donzeau, A., Briet, C., & Coutant, R. (2025) · EMC - Pédiatrie - Maladies infectieuses · doi:10.1016/s1637-5017(25)85172-x
Peripheral Precocious Puberty: Interventions to Improve Growth
Haddad, N. G., & Eugster, E. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1795-9_71
Hiperplasia suprarrenal congénita: formas precoces
Levaillant, L., Bouhours-Nouet, N., Rouleau, S., Amsellem-Jager, J., Donzeau, A., Briet, C., & Coutant, R. (2025) · EMC - Pediatría · doi:10.1016/s1245-1789(25)51124-1
Kolli, V., Trick, J., Schulman, A., Iben, J., Padilla, C. J., Li, T., Faucz, F. R., & Merke, D. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1784619
Çetin, K., Çetiner, E. B., Bahar, Y. F., Tırtar, A., Parlak, M., & Tuhan, H. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0101
“Adequate glucocorticoid and mineralocorticoid replacement is required to suppress ACTH-driven androgen excess, yet optimal dosing is di ffi cult because even mild overtreatment may impair growth [6, 8].”
Nokoff, N., Fechner, P. Y., Kim, M. S., Marshall, I. H., Merke, D. P., Sarafoglou, K., Hartzell, A. L., Lin, V. H., & Thornton, P. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag192
Kim, H., Lin, V. H., Newfield, R. S., Dauber, A., Luo, M., Cicero, S., Li, M., Zhao, C., & Cheng, H. K.-H. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag112
Growth patterns in patients with congenital adrenal hyperplasia analyzed by the QEPS growth model
Navardauskaitė, R., Niklasson, A., Nierop, A. F. M., Pivodic, A., Verkauskienė, R., & Holmgren, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1736405
“Height just before puberty, at onset of puberty, and gain during the pubertal years is important for adult height, with earlier onset/timing and sometimes less pubertal growth observed in patients with CAH compared with the general population (2, 36).”
InfluentialTizianel, I., Ceccato, F., & Barbot, M. (2026) · Frontiers in Adolescent Medicine · doi:10.3389/fradm.2026.1827315
Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia
Goai, W. H., & Torpy, D. J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2695099
“…than those treated with prednisone (−0.9 versus −1.6, p < 0.01); however, hydrocortisone-equivalent glucocorticoid doses were also higher in the prednisone-treated group at the onset of puberty, and final height correlated negatively with glucocorticoid dose at puberty ( r = −0.3, p < 0.05) [26].”
InfluentialGürbüz, E., Kocaay, P., Çetin, S. K., Tepe, D., Genç, C. A., Demirtaş, Ş., Boyraz, M., Keçeli, A. M., & Gürbüz, F. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02984-3
Çelik, N. B., Şenkalfa, B., Vurallı, D., Özön, Z. A., & Gonc, E. N. (2026) · Kırıkkale Üniversitesi Tıp Fakültesi Dergisi · doi:10.24938/kutfd.1829514
Assessment of Physical Growth in Children with Congenital Adrenal Hyperplasia (CAH)
Czapla, Z., Niedziela, M., & Cieślik, J. J. (2008) · Repozytorium Uniwersytetu im. Adama Mickiewicza (Adam Mickiewicz University in Poznań)
Metadata
- Authors
- Bonfig, W., Bechtold, S., Schmidt, H., Knorr, D., & Schwarz, H. P.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Bonfig, Walter
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-05-01
- Volume
- 92
- Issue
- 5
- Pages
- 1635-1639
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160090915
- Cited by
- 167
- References
- 40
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 10 · 2021: 7 · 2020: 6 · 2019: 15 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 1 · 2014: 8 · 2013: 11 · 2012: 6
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, adult height, prednisone, cortisol, glucocorticoid therapy, growth rate, puberty, pubertal growth, simple virilizing CAH, salt-wasting CAH, menarche, growth hormone therapy, genetic potential, dose-response relationship, short stature, children and adolescents, sex differences, puberty timing
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Body Height, Breast, Child, Female, Growth, Hormones, Humans, Hydrocortisone, Male, Prednisone, Puberty, Retrospective Studies, Steroid 21-Hydroxylase, Testis, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.